Ideaya Biosciences Begins Trial of IDE196, Xalkori in Uveal Melanoma Patients

Source: genomeweb, January 2021

San Francisco-based Ideaya Biosciences on Tuesday said that it has dosed its first uveal melanoma patient in a clinical trial evaluating its PKC inhibitor IDE196 with Pfizer’s cMET inhibitor crizotinib (Xalkori).

Ideaya, which develops precision oncology drugs for patients selected using molecular diagnostics, is evaluating the IDE196-crizotinib combination in metastatic uveal melanoma patients following results from preclinical research demonstrating synergistic activity between the two agents.

Mick O’Quigley, Ideaya’s VP and head of development operations, said in a statement that the company decided to advance the combination to clinical trials based on translational research that included evaluation of cMET expression in samples from metastatic uveal melanoma patients.

READ THE ORIGINAL FULL ARTICLE